Debio 1143 Combined with Concurrent High-Dose Cisplatin Chemoradiotherapy in Patients with High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double Blind, Randomised, Placebo Controlled, Multicentre Phase 2 Study (GORTEC 2015-03)

SSRN Electronic Journal ◽

10.2139/ssrn.3552860 ◽

2020 ◽

Author(s):

Xu-Shan Sun ◽

Yungan Tao ◽

Christophe Le Tourneau ◽

Yoann Pointreau ◽

Christian Sire ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Multicentre Phase ◽

Phase 2 Study

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30327-2 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1173-1187 ◽

Cited By ~ 6

Author(s):

Xu-Shan Sun ◽

Yungan Tao ◽

Christophe Le Tourneau ◽

Yoann Pointreau ◽

Christian Sire ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Study

Faculty Opinions recommendation of Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738449325.793581438 ◽

2020 ◽

Author(s):

Sandra Nuyts ◽

Heleen Bollen

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Study

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

Annals of Oncology ◽

10.1093/annonc/mdz394.062 ◽

2019 ◽

Vol 30 ◽

pp. v902 ◽

Cited By ~ 2

Author(s):

J. Bourhis ◽

X. Sun ◽

Y. Pointreau ◽

C. Sire ◽

C. Le Tourneau ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Double Blind ◽

Randomized Phase Ii ◽

Risk Patients

An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps6102 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS6102-TPS6102 ◽

Cited By ~ 3

Author(s):

Bhumsuk Keam ◽

Makoto Tahara ◽

Jin-Ching Lin ◽

Assuntina Gesualda Sacco ◽

Bohuslav Melichar ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Phase 2 Study ◽

International Multicenter

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30737-3 ◽

2021 ◽

Vol 22 (4) ◽

pp. 450-462

Author(s):

Nancy Y Lee ◽

Robert L Ferris ◽

Amanda Psyrri ◽

Robert I Haddad ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Standard Of Care ◽

Advanced Squamous Cell Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase

LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2269 ◽

2020 ◽

Vol 31 ◽

pp. S1168

Author(s):

J. Bourhis ◽

X. Sun ◽

C. Le Tourneau ◽

Y. Pointreau ◽

C. Sire ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Locally Advanced ◽

High Dose ◽

Advanced Squamous Cell Carcinoma ◽

Double Blind ◽

Randomized Phase Ii ◽

Risk Patients

Update of a Phase 2 Study of Definitive Radiation Therapy With Concurrent Docetaxel and Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.11.063 ◽

2014 ◽

Vol 88 (2) ◽

pp. 480-481

Author(s):

M. Yao ◽

C. Woods ◽

P. Savvides ◽

P. Lavertu ◽

R. Rezaee ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Radiation Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Study

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

Annals of Oncology ◽

10.1093/annonc/mdw376.69 ◽

2016 ◽

Vol 27 ◽

pp. vi350 ◽

Cited By ~ 1

Author(s):

R. Haddad ◽

M. Gillison ◽

R.L. Ferris ◽

K. Harrington ◽

M. Monga ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Phase 2 Study ◽

Metastatic Squamous Cell Carcinoma

Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.1234 ◽

2013 ◽

Vol 87 (2) ◽

pp. S466-S467 ◽

Cited By ~ 2

Author(s):

M.D. Mix ◽

M. Jameson ◽

M. Tills ◽

S. Dibaj ◽

A. Groman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Multicenter Phase

Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS)

10.1158/1535-7163.targ-15-a66 ◽

2015 ◽

Cited By ~ 2

Author(s):

Victoria Jackson ◽

Shevan Silva ◽

Maria Abbattista ◽

Christopher Guise ◽

Matthew Bull ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Study ◽

Egfr Tki ◽

Ongoing Phase